Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study

Viking Therapeutics' shares plunged 42% following mixed top-line data from its Phase II VENTURE-Oral study for the experimental obesity drug VK2735. While the study met its primary and secondary endpoints, demonstrating up to 12.2% body weight reduction in 13 weeks, a significantly higher patient discontinuation rate of 28% for VK2735 versus 18% for placebo raised concerns about the drug's tolerability. This sell-off, mirroring recent setbacks for other oral obesity drug candidates, highlights the critical importance of tolerability in the competitive and rapidly expanding obesity market.

Analysis

Viking Therapeutics (VKTX) shares collapsed by 42% following the release of top-line data from its phase II VENTURE-Oral study, which presented a mixed profile for its experimental obesity drug, VK2735. While the study successfully met its efficacy endpoints, demonstrating a significant, progressive weight loss of up to 12.2% at the highest dose over 13 weeks, this positive result was critically undermined by a poor tolerability profile. The patient discontinuation rate in the VK2735 arms was 28%, substantially higher than the 18% rate observed in the placebo group, raising significant concerns about the drug's commercial viability and potential for patient adherence. This adverse event data not only triggered the steep sell-off but also reportedly dampened the company's prospects as an acquisition target. The setback for VKTX mirrors a similar challenge recently faced by Eli Lilly with its oral obesity candidate, suggesting that achieving an acceptable balance between efficacy and tolerability is a major hurdle for the entire class of oral GLP-1 drugs. In this highly competitive landscape, which Goldman Sachs projects to reach $100 billion by 2030, these difficulties contrast with the strengthening position of Novo Nordisk, which appears poised to become the first to market an oral obesity pill.

Key Decisions for Investors

• Investors should recognize that the investment thesis for Viking Therapeutics has materially weakened, as the high patient discontinuation rate for VK2735 introduces a significant risk to its regulatory and commercial pathway, and diminishes its near-term M&A appeal.
• The tolerability challenges seen in both Viking's and Eli Lilly's trials highlight a systemic issue for oral obesity treatments, warranting increased scrutiny of patient dropout rates as a key metric in assessing competitors in this space.
• Consider that Novo Nordisk's competitive moat may be widening, as repeated clinical setbacks from rivals reinforce its potential first-mover advantage in the oral obesity drug market.
• Monitor future communications from Viking for any plans to address the tolerability issues, such as dose titration strategies or formulation changes, as this will be critical to salvaging the program's value.